Mulugeta Mamo

Publications by Year

Research Areas

Neurological diseases and metabolism, RNA regulation and disease, Synthesis and biological activity, Melanoma and MAPK Pathways, PI3K/AKT/mTOR signaling in cancer

Most-Cited Works

• → Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo(2005)244 cited
• → Syntheses of Potent, Selective, and Orally Bioavailable Indazole-Pyridine Series of Protein Kinase B/Akt Inhibitors with Reduced Hypotension(2007)62 cited
• → Design and synthesis of pyridine–pyrazolopyridine-based inhibitors of protein kinase B/Akt(2007)62 cited
• → Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers(2017)44 cited
• → Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors(2017)40 cited
• → Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design(2018)39 cited
• → Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic(2019)38 cited
• → Facilitating unambiguous NMR assignments and enabling higher probe density through selective labeling of all methyl containing amino acids(2016)34 cited
• → Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity(2018)33 cited
• → 2-Pyridyl P1′-Substituted Symmetry-Based Human Immunodeficiency Virus Protease Inhibitors (A-792611 and A-790742) with Potential for Convenient Dosing and Reduced Side Effects(2009)30 cited